🩺What is Gestational Hypertension?
Preeclampsia is a hypertensive disorder of pregnancy affecting 2-8% of pregnancies worldwide and a leading cause of maternal and perinatal morbidity and mortality. The ACOG (American College of Obstetricians and Gynecologists) screening approach classifies patients into high-risk (any one of six factors: previous preeclampsia, multifetal gestation, chronic hypertension, pregestational diabetes, renal disease, or autoimmune disease) and moderate-risk categories (nulliparity, obesity BMI >30, family history of preeclampsia, maternal age ≥35, interpregnancy interval >10 years, or IVF pregnancy). Patients with any single high-risk factor or two or more moderate-risk factors are recommended low-dose aspirin (81 mg) prophylaxis starting between 12-16 weeks of gestation to reduce the risk of developing preeclampsia.
📊Clinical Assessment & Risk Scoring
Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Gestational Hypertension:
Preeclampsia Risk Assessment (ACOG)
The Preeclampsia Risk Assessment tool screens pregnant patients for high-risk and moderate-risk factors to determine the need for low-dose aspirin prophylaxis, based on ACOG Practice Bulletin recommendations.
🧬Diagnostic Logic & Scoring Breakdown
The Preeclampsia Risk Assessment is not a numerical score but a categorical screening tool. The clinician checks for the presence of each risk factor. If the patient has any one of the six high-risk factors (previous preeclampsia, multifetal gestation, chronic hypertension, pregestational diabetes, renal disease, or autoimmune disease such as SLE or APS), they are classified as HIGH RISK and aspirin prophylaxis is recommended. If the patient has no high-risk factors, the moderate-risk factors are counted: nulliparity, BMI >30, family history of preeclampsia, age ≥35, interpregnancy interval >10 years, and IVF pregnancy. If two or more moderate-risk factors are present, the patient is also classified as HIGH RISK. If exactly one moderate-risk factor is present, the patient is classified as MODERATE RISK and aspirin may be considered. If no risk factors are present, the patient is LOW RISK. This approach follows the 2018 ACOG Practice Bulletin No. 202 and the USPSTF 2021 recommendation on aspirin prophylaxis for preeclampsia prevention.
📢Clinical Significance & Implications
Preeclampsia affects 2-8% of pregnancies and is a leading cause of maternal mortality worldwide, responsible for an estimated 50,000-70,000 maternal deaths annually. The ACOG screening approach, endorsed by USPSTF, identifies patients at increased risk who benefit from low-dose aspirin prophylaxis, which reduces the risk of preeclampsia by approximately 24%, preterm birth by 15%, and IUGR by 20%. Aspirin prophylaxis is most effective when started before 16 weeks of gestation. This screening tool is designed for the first prenatal visit to guide timely prophylaxis initiation.
💡 Clinical Assessment Scenario Example
A 36-year-old primigravida (first pregnancy, nulliparous), BMI 32, with a family history of preeclampsia (her mother had severe preeclampsia). No high-risk factors. Moderate-risk factors: nulliparity (1), BMI >30 (1), maternal age ≥35 (1), family history of preeclampsia (1). Total moderate-risk factors: 4. Since ≥2 moderate-risk factors are present, she is classified as HIGH RISK. Recommendation: Low-dose aspirin (81 mg) daily starting between 12-16 weeks of gestation, calcium supplementation (1 g/day) if dietary intake is low, weekly BP monitoring, and serial growth ultrasounds.
💊Common Medications & Interventions
The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Gestational Hypertension:
⚠️Clinical Assessment Pitfalls
❌ Mistake: Counting gestational hypertension or preeclampsia in the current pregnancy as a risk factor
✅ Correction: This screening is performed at the first prenatal visit to predict risk. Current gestational hypertension or preeclampsia is a diagnosis, not a risk factor for the same pregnancy.
❌ Mistake: Starting aspirin after 16 weeks of gestation
✅ Correction: Aspirin prophylaxis should be initiated between 12-16 weeks for maximal benefit. Starting after 16 weeks significantly reduces efficacy in preventing preeclampsia.
🚑When to Seek Medical Attention
This reference supports clinical assessment of Gestational Hypertension; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.
❓Frequently Asked Questions
Q: When should aspirin prophylaxis for preeclampsia be started?
Low-dose aspirin (81 mg) should be initiated between 12 and 16 weeks of gestation for maximum benefit. Starting before 12 weeks has not been adequately studied, and starting after 16 weeks significantly reduces efficacy. The medication should be continued until delivery, typically at 36-37 weeks or as determined by the obstetric provider.
Q: What defines a high-risk factor for preeclampsia according to ACOG?
ACOG defines six high-risk factors: (1) History of preeclampsia in a previous pregnancy, (2) Multifetal gestation (twins, triplets, or more), (3) Chronic hypertension (pre-existing hypertension), (4) Pregestational diabetes (type 1 or type 2, not gestational), (5) Renal disease (including chronic kidney disease, glomerulonephritis, etc.), and (6) Autoimmune disease (systemic lupus erythematosus or antiphospholipid syndrome). The presence of any one of these factors qualifies the patient as high risk and aspirin is recommended.
Q: What is the role of calcium supplementation in preeclampsia prevention?
Calcium supplementation (1 g/day, i.e., 1,000 mg) is recommended by ACOG and the WHO for pregnant women with low dietary calcium intake to reduce the risk of preeclampsia. Studies show that calcium supplementation reduces the risk of preeclampsia by approximately 50% in women with low baseline calcium intake. It is particularly important in populations with low dietary calcium consumption and is used adjunctively with aspirin prophylaxis in high-risk patients.